Abstract
This chapter describes the clinical features, and diagnosis of complications in AECHB including secondary bacterial infections, coagulation disorder, water electrolyte disorder, hepatorenal syndrome, hepatic encephalopathy, hepatopulmonary syndrome and endotoxemia
-
1.
Patients with severe hepatitis have impaired immunity and are therefore vulnerable to all kinds of infections. After infection, these patients may experience shock, DIC and multiple organ failure, all of which seriously affect their prognosis and are major causes of death. Concurrent infections consist primarily of infections of the lungs, intestines, biliary tract, and urinary tract, as well as spontaneous bacterial peritonitis and sepsis.
-
2.
Severe hepatitis may reduce the synthesis of coagulation factors and enhance their dysfunction and increase anticoagulants and platelet abnormalities, leading to coagulopathy. Infection, hepatorenal syndrome and complications can further aggravate coagulopathy, resulting in DIC and seriously affecting patient prognosis.
-
3.
Hepatorenal syndrome, which is characterized by renal failure, hemodynamic changes in arterial circulation and abnormalities in the endogenous vascular system, is a common clinical complication of end-stage liver disease, and one of the important indicators for the prognosis of patients with severe hepatitis.
-
4.
Water electrolyte disorder (water retention, hyponatremia, hypokalemia, hyperkalaemia) and acid-base imbalance are common in patients with severe hepatitis. These internal environment disorders can lead to exacerbation and complication of the illness.
-
5.
Hepatic encephalopathy is a neurological and psychiatric anomaly syndrome based on metabolic disorder, and an important prognostic indicator for patients with severe hepatitis.
-
6.
The hepatopulmonary syndrome is an important vascular complication in lungs due to systemic hypoxemia in patients with cirrhosis and portal hypertension. The majority of patients with HPS are asymptomatic. Long-term oxygen therapy remains the most frequently recommended therapy for symptoms in patients with severe hypoxemia.
-
7.
Endotoxemia, an important complication of severe hepatitis, is not only a second hit to the liver, but also leads to other complications including SIRS and MODS.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Change history
02 August 2019
The original version of the book was inadvertently published with spelling errors in author names. The names have been corrected and details of the changes have been provided below.
References
Bajaj JS, O’Leary JG, Reddy KR, Wong F, Biggins SW, Patton H, Fallon MB, Garcia-Tsao G, Maliakkal B, Malik R, Subramanian RM, Thacker LR, Kamath PS, North American Consortium For The Study Of End-Stage Liver Disease N. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology. 2014;60:250–6.
Zhang Z, Lu J, Liu M, Wang Y, Qu G, Li H, Wang J, Pang Y, Liu C, Zhao Y. Genotyping and molecular characteristics of multidrug-resistant Mycobacterium tuberculosis isolates from China. J Infect. 2015;70:335–45.
Godbole G, Shanmugam N, Dhawan A, Verma A. Infectious complications in pediatric acute liver failure. J Pediatr Gastroenterol Nutr. 2011;53:320–5.
Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease. Liver Int. 2006;26:1175–86.
Acharya SK, Dasarathy S, Irshad M. Prospective study of plasma fibronectin in fulminant hepatitis: association with infection and mortality. J Hepatol. 1995;23:8–13.
Qin X, Gao B. The complement system in liver diseases. Cell Mol Immunol. 2006;3:333–40.
Wyke RJ, Yousif-Kadaru AG, Rajkovic IA, Eddleston AL, Williams R. Serum stimulatory activity and polymorphonuclear leucocyte movement in patients with fulminant hepatic failure. Clin Exp Immunol. 1982;50:442–9.
Sun S, Guo Y, Zhao G, Zhou X, Li J, Hu J, Yu H, Chen Y, Song H, Qiao F, Xu G, Yang F, Wu Y, Tomlinson S, Duan Z, Zhou Y. Complement and the alternative pathway play an important role in LPS/D-GalN-induced fulminant hepatic failure. PLoS One. 2011;6:e26838.
Taylor NJ, Manakkat Vijay GK, Abeles RD, Auzinger G, Bernal W, Ma Y, Wendon JA, Shawcross DL. The severity of circulating neutrophil dysfunction in patients with cirrhosis is associated with 90-day and 1-year mortality. Aliment Pharmacol Ther. 2014;40:705–15.
Taylor NJ, Nishtala A, Manakkat Vijay GK, Abeles RD, Auzinger G, Bernal W, Ma Y, Wendon JA, Shawcross DL. Circulating neutrophil dysfunction in acute liver failure. Hepatology. 2013;57:1142–52.
Liu H, Zhang H, Wan G, Sang Y, Chang Y, Wang X, Zeng H. Neutrophil-lymphocyte ratio: a novel predictor for short-term prognosis in acute-on-chronic hepatitis B liver failure. J Viral Hepat. 2014;21:499–507.
Metelitsa LS, Naidenko OV, Kant A, Wu HW, Loza MJ, Perussia B, Kronenberg M, Seeger RC. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol. 2001;167:3114–22.
Notas G, Kisseleva T, Brenner D. NK and NKT cells in liver injury and fibrosis. Clin Immunol. 2009;130:16–26.
Tripathy AS, Das R, Chadha MS, Arankalle VA. Epidemic of hepatitis B with high mortality in India: association of fulminant disease with lack of CCL4 and natural killer T cells. J Viral Hepat. 2011;18:e415–22.
Dong X, Gong Y, Zeng H, Hao Y, Wang X, Hou J, Wang J, Li J, Zhu Y, Liu H, Han J, Zhou H, Shen L, Gao T, Zhou T, Yang S, Li S, Chen Y, Meng Q, Li H. Imbalance between circulating CD4+ regulatory T and conventional T lymphocytes in patients with HBV-related acute-on-chronic liver failure. Liver Int. 2013;33:1517–26.
Zou Z, Xu D, Li B, Xin S, Zhang Z, Huang L, Fu J, Yang Y, Jin L, Zhao JM, Shi M, Zhou G, Sun Y, Wang FS. Compartmentalization and its implication for peripheral immunologically-competent cells to the liver in patients with HBV-related acute-on-chronic liver failure. Hepatol Res. 2009;39:1198–207.
Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, Chisari FV. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol. 2003;77:68–76.
Ye Y, Liu J, Lai Q, Zhao Q, Peng L, Xie C, Zhang G, Zhang S, Zhang Y, Zhu J, Huang Y, Hu Z, Xie D, Lin B, Gao Z. Decreases in activated CD8+ T cells in patients with severe hepatitis B are related to outcomes. Dig Dis Sci. 2015;60:136–45.
Zhang JY, Zhang Z, Lin F, Zou ZS, Xu RN, Jin L, Fu JL, Shi F, Shi M, Wang HF, Wang FS. Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology. 2010;51:81–91.
Fernandez J, Acevedo J, Castro M, Garcia O, de Lope CR, Roca D, Pavesi M, Sola E, Moreira L, Silva A, Seva-Pereira T, Corradi F, Mensa J, Gines P, Arroyo V. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology. 2012;55:1551–61.
Pinzone MR, Celesia BM, Di Rosa M, Cacopardo B, Nunnari G. Microbial translocation in chronic liver diseases. Int J Microbiol. 2012;2012:694629.
Rai R, Saraswat VA, Dhiman RK. Gut microbiota: its role in hepatic encephalopathy. J Clin Exp Hepatol. 2015;5:S29–36.
Bauer TM, Schwacha H, Steinbruckner B, Brinkmann FE, Ditzen AK, Aponte JJ, Pelz K, Berger D, Kist M, Blum HE. Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol. 2002;97:2364–70.
Wang XD, Soltesz V, Andersson R, Bengmark S. Bacterial translocation in acute liver failure induced by 90 per cent hepatectomy in the rat. Br J Surg. 1993;80:66–71.
Verbeke L, Nevens F, Laleman W. Bench-to-beside review: acute-on-chronic liver failure - linking the gut, liver and systemic circulation. Crit Care. 2011;15:233.
Fukui H. Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. World J Hepatol. 2015;7:425–42.
Su HB, Wang HF, Lin F, Xu HM, Zhao H, Li L, Yan T, Mou JS, Li C. Retrospective study of liver failure complicated with bacterium and fungous infection. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2007;21:229–31.
Zhang XH, Zhang GH, Man CJ, He FM. Clinical study on the severe hepatitis with nosocomial fungal infections and risk factors. Zhonghua Gan Zang Bing Za Zhi. 2004;12:389–91.
Koulaouzidis A. Diagnosis of spontaneous bacterial peritonitis: an update on leucocyte esterase reagent strips. World J Gastroenterol. 2011;17:1091–4.
Koulaouzidis A, Bhat S, Saeed AA. Spontaneous bacterial peritonitis. World J Gastroenterol. 2009;15:1042–9.
Madrid AM, Cumsille F, Defilippi C. Altered small bowel motility in patients with liver cirrhosis depends on severity of liver disease. Dig Dis Sci. 1997;42:738–42.
Chiva M, Guarner C, Peralta C, Llovet T, Gomez G, Soriano G, Balanzo J. Intestinal mucosal oxidative damage and bacterial translocation in cirrhotic rats. Eur J Gastroenterol Hepatol. 2003;15:145–50.
Ramachandran A, Prabhu R, Thomas S, Reddy JB, Pulimood A, Balasubramanian KA. Intestinal mucosal alterations in experimental cirrhosis in the rat: role of oxygen free radicals. Hepatology. 2002;35:622–9.
European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417.
Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57:1651–3.
Rimola A, Garcia-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, Inadomi JM. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol. 2000;32:142–53.
Eccles S, Pincus C, Higgins B, Woodhead M. Diagnosis and management of community and hospital acquired pneumonia in adults: summary of NICE guidance. BMJ. 2014;349:g6722.
Mandell LA. Community-acquired pneumonia: An overview. Postgrad Med. 2015;127:607–15.
Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol. 1993;18:353–8.
Rolando N, Kramer DJ. Scenario number one: sepsis and ARDS before liver transplantation. Liver Transpl Surg. 1997;3:60–75.
Rolando N, Harvey F, Brahm J, Philpott-Howard J, Alexander G, Casewell M, Fagan E, Williams R. Fungal infection: a common, unrecognised complication of acute liver failure. J Hepatol. 1991;12:1–9.
Hassan EA, Abd El-Rehim AS, Hassany SM, Ahmed AO, Elsherbiny NM, Mohammed MH. Fungal infection in patients with end-stage liver disease: low frequency or low index of suspicion. Int J Infect Dis. 2014;23:69–74.
Kups J, Wozniakowska-Gesicka T, al-Batool K. Fungal infection in the course of acute liver failure. Pol Merkur Lekarski. 2002;13:165–7.
Chen J, Yang Q, Huang J, Li L. Risk factors for invasive pulmonary aspergillosis and hospital mortality in acute-on-chronic liver failure patients: a retrospective-cohort study. Int J Med Sci. 2013;10:1625–31.
Shroff S, Shroff GS, Yust-Katz S, Olar A, Tummala S, Tremont-Lukats IW. The CT halo sign in invasive aspergillosis. Clin Case Rep. 2014;2:113–4.
Deeren DH. The Importance of Previous CT Scans in the Diagnosis of Invasive Pulmonary Aspergillosis. Ther Adv Hematol. 2011;2:121–2.
Caillot D, Latrabe V, Thiebaut A, Herbrecht R, De Botton S, Pigneux A, Monchecourt F, Mahi L, Alfandari S, Couaillier JF. Computer tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia: an useful tool for diagnosis and assessment of outcome in clinical trials. Eur J Radiol. 2010;74:e172–5.
Docke WD, Prosch S, Fietze E, Kimel V, Zuckermann H, Klug C, Syrbe U, Kruger DH, von Baehr R, Volk HD. Cytomegalovirus reactivation and tumour necrosis factor. Lancet. 1994;343:268–9.
Varani S, Lazzarotto T, Margotti M, Masi L, Gramantieri L, Bolondi L, Landini MP. Laboratory signs of acute or recent cytomegalovirus infection are common in cirrhosis of the liver. J Med Virol. 2000;62:25–8.
Knollmann FD, Maurer J, Bechstein WO, Vogl TJ, Neuhaus P, Felix R. Pulmonary disease in liver transplant recipients. Spectrum of CT features. Acta Radiol. 2000;41:230–6.
Dhiman RK, Saraswat VA, Rajekar H, Reddy C, Chawla YK. A guide to the management of tuberculosis in patients with chronic liver disease. J Clin Exp Hepatol. 2012;2:260–70.
Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007;146:340–54.
Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149:177–84.
Ferrara G, Losi M, Meacci M, Meccugni B, Piro R, Roversi P, Bergamini BM, D’Amico R, Marchegiano P, Rumpianesi F, Fabbri LM, Richeldi L. Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med. 2005;172:631–5.
Gangadharam PR. Microbiology of nontuberculosis mycobacteria. Semin Respir Infect. 1996;11:231–43.
Atilla A, Aydin S, Demirdoven AN, Kilic SS. Severe toxoplasmic hepatitis in an immunocompetent patient. Jpn J Infect Dis. 2015;
Bartelt LA, Sartor RB. Advances in understanding Giardia: determinants and mechanisms of chronic sequelae. F1000Prime Rep. 2015;7:62.
Buonfrate D, Formenti F, Perandin F, Bisoffi Z. Novel approaches to the diagnosis of Strongyloides stercoralis infection. Clin Microbiol Infect. 2015;21:543–52.
Nakajima T. Roles of sulfur metabolism and rhodanese in detoxification and anti-oxidative stress functions in the liver: responses to radiation exposure. Med Sci Monit. 2015;21:1721–5.
Muciñobermejo J, Carrilloesper R, Uribe M, et al. Coagulation abnormalities in the cirrhotic patient. Ann Hepatol. 2013;12:713–24.
Mihaila R, Dragomir I. Advances of knowledge on coagulation disorders in liver cirrhosis and their clinical consequences. Biomed Res. 2015;26:625–32.
Mirsaeva GK, Mironchuk NN. Features of coagulation hemostasis and anticoagulation system in patients with chronic heart failure due to ischemic heart disease. Kazan Med J. 2015;96(5):716–22.
Valla DC, Rautou PE. The coagulation system in patients with end-stage liver disease. Liver Int. 2015;35(Suppl 1):139–44.
Jeon YJ, Kim YR, Bo EL, et al. Association of five common polymorphisms in the plasminogen activator inhibitor-1 gene with primary ovarian insufficiency. Fertil Steril. 2014;101:825–32.
Okafor ON, Gorog DA. Endogenous fibrinolysis: an important mediator of thrombus formation and cardiovascular risk. J Am Coll Cardiol. 2015;65:1683–99.
Pallister CJ, Watson MS. Haematology. Banbury: Scion; 2010. p. 336–47. isbn:1-904842-39-9.
Heinz S, Braspenning J. Measurement of blood coagulation factor synthesis in cultures of human hepatocytes. Methods Mol Biol. 2015;1250:309–16.
Kopec AK, Luyendyk JP. Coagulation in liver toxicity and disease: Role of hepatocyte tissue factor. Thromb Res. 2014;133:S57–9.
Valla DC, Rautou PE. The coagulation system in patients with end-stage liver disease. Liver Int. 2015;35(Suppl 1):139–44.
Gutenberg P. Coagulation factor V deficiency. Phlebology. 2016;34:160–6.
Pluta A, Gutkowski K, Hartleb M. Treatment of coagulopathies in severe liver disease. Postepy Nauk Medycznych. 2010:63–8.
Jin YH, Wang MS, Zheng FX, et al. Molecular genetics and clinical features of nine patients with inherited coagulation factor VII deficiency. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2012;29:404–7.
Math SK, Sanders MA, Hollensead SC. Unexpected laboratory diagnosis: Acquired dysfibrinogenemia in a bleeding patient with liver disease. MLO Med Lab Obs. 2010;42
Chen W, Wang D, Ni N, et al. A fast and simple approach to the quantitative evaluation of fibrinogen coagulation. Biotechnol Lett. 2014;36:337–40.
Schroeder V, Handrková H, Dodt J, et al. Free factor XIII activation peptide affects factor XIII function. Br J Haematol. 2014;168:757–9.
Komáromi I, Bagoly Z, Muszbek L. Factor XIII: novel structural and functional aspects. J Thromb Haemost. 2011;9:9–20.
Samis JA, Stewart KA, Nesheim ME, et al. Factor V cleavage and inactivation are temporally associated with elevated elastase during experimental sepsis. J Thromb Haemost. 2007;5:2559–61.
Wheeler AP, Gailani D. The intrinsic pathway of coagulation as a target for antithrombotic therapy. Hematol Oncol Clin North Am. 2016;30:1099–114.
Kozarcanin H, Lood C, Munthe-Fog L, et al. The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation. J Thromb Haemost. 2016;14:802–7.
Annich GM. Extracorporeal life support: the precarious balance of hemostasis. J Thromb Haemost. 2015, 13 Suppl 1:S336–42.
Chalupa P, Holub M. Favorable Outcome of Severe Acute Hepatitis B in a Patient Treated with Antithrombin III and Antiviral Therapy. Clin Infect Dis. 2009;49:481.
Huang N, Rodriguez R L, Hagie F E, et al. Monocot seed product comprising a human serum albumin protein: US, US 8158857 B2[P]. 2012.
Kutcher ME, Ferguson AR, Cohen MJ. A principal component analysis of coagulation after trauma. J Trauma Injury Infect Crit Care. 2013;74:1223–9.
Okamoto K, Tamura T, Yamaguchi K. Clinical trials of anticoagulants and anticoagulant factor concentrates for the management of DIC in Japan. Rinsho Byori. 2011;Suppl 147:95–103.
Mann HJ, Short MA, Schlichting DE. Protein C in critical illness. Am J Health Syst Pharm. 2009;66:1089–96.
Kruithof EK, Dunoyer-Geindre S. Human tissue-type plasminogen activator. Thromb Haemost. 2014;112:243–54.
Jankun J, Aleem AM, Selman SH, et al. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis. Int J Mol Med. 2007;20:683–7.
Martí-Carvajal AJ, Cardona AF, Simancas D. Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. Cochrane Database Syst Rev. 2015;66:1–2.
Frith D, Brohi K. The pathophysiology of trauma-induced coagulopathy. Curr Opin Crit Care. 2012;18(6):631–6.
Agren A, Wiman B, Schulman S. Laboratory evidence of hyperfibrinolysis in association with low PAI-1 activity. Blood Coagul Fibrinolysis. 2007;18:657–60.
Carvalho M, Rodrigues A, Gomes M, et al. Interventional algorithms for the control of coagulopathic bleeding in surgical, trauma, and postpartum settings: recommendations from the Share Network Group. Clin Appl Thromb Hemost. 2016;22:1593–600.
Surawong A, Rojnuckarin P, Juntiang J, et al. Hyperfibrinolysis and the risk of hemorrhage in stable cirrhotic patients. Asian Biomed. 2010;4:199–206.
Fohlen-Walter A, Maistre ED, Mulot A, et al. Does negative heparin-platelet factor 4 enzyme-linked immunosorbent assay effectively exclude heparin-induced thrombocytopenia? J Thromb Haemost. 2003;1:1844–5.
Lehmann JP. Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism. Crit Care. 2011;15:1–10.
Yousif M, Hassanein O, Salim I, Said N. Role of endogenous heparinoids and bacerial infection in bleeding from esophageal varices complicating liver cirrhosis. J Hepatol. 50:S284.
Blich M, Golan A, Arvatz G, et al. Macrophages activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arterioscler Thromb Vasc Biol. 2013;33:e56–65.
Lentz BR. Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Prog Lipid Res. 2003;42:423–38.
Kuharsky AL, Fogelson AL. Surface-mediated control of blood coagulation: the role of binding site densities and platelet deposition. Biophys J. 2001;80:1050–74.
Crow AR, Leytin V, Starkey AF, et al. CD154 (CD40 ligand)-deficient mice exhibit prolonged bleeding time and decreased shear-induced platelet aggregates. J Thromb Haemost. 2003;1:850–2.
Jiang XW, Fei G, Yan M, et al. Percutaneous microwave ablation in the spleen for treatment of hypersplenism in cirrhosis patients. Digest Dis Sci. 2015;61:1–6.
Tomikawa M, Akahoshi T, Sugimachi K, et al. Laparoscopic splenectomy may be a superior supportive intervention for cirrhotic patients with hypersplenism. J Gastroenterol Hepatol. 2010;25:397–402.
Kuter DJ, Gernsheimer TB. Thrombopoietin and platelet production in chronic immune thrombocytopenia. Hematol Oncol Clin North Am. 2009;23:1193–211.
Bachman DE, Forman MA, Hostutler RA, et al. Prospective diagnostic accuracy evaluation and clinical utilization of a modified assay for platelet-associated immunoglobulin in thrombocytopenic and nonthrombocytopenic dogs. Vet Clin Pathol. 2015;44:355–68.
Melissa V. Chan, Rebecca B. M. Knowles, Lundberg M H, et al. P2Y 12, receptor blockade synergises strongly with nitric oxide and prostacyclin to inhibit platelet activation. Br J Clin Pharmacol, 2015, 81:621–633.
De Haas CJC, Weeterings C, Vughs MM, et al. Staphylococcal superantigen-like 5 activates platelets and supports platelet adhesion under flow conditions, which involves glycoprotein Ibα and α IIb β 3. J Thromb Haemost. 2009;7:1867–74.
Soares CV, Lima A, et al. Liver disease and gastrointestinal bleeding in hereditary haemorrhagic telangiectasia - case report. Jornal Português De Gastrenterologia. 2010:213–6.
Philips C, Mukhopadhyay P. Hemostasis, disorders of coagulation and transfusion in cirrhosis. J Franklin Inst. 2015;64:123–4.
Arroyo V, Fernandez J, Ginès P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis. 2008;28:81–95.
Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008;28:26–42.
Cho J, Sun MC, Yu SJ, et al. Bleeding complications in critically ill patients with liver cirrhosis. Korean J Intern Med. 2013;31:288–95.
Sillermatula JM, Schwameis M, Blann A, et al. Thrombin as a multi-functional enzyme. Focus on in vitro and in vivo effects. Thromb Haemost. 2011;106:1020–33.
Tripodi A, Anstee QM, Sogaard KK, et al. Hypercoagulability in cirrhosis: causes and consequences 1. J Thromb Haemost. 2011;9:1713–23.
Presseizen K, Friedman Z, Shapiro H, et al. Phosphatidylserine expression on the platelet membrane of patients with myeloproliferative disorders and its effect on platelet-dependent thrombin formation. Clin Appl Thromb Hemost. 2002;8:33–9.
Ali M, Ananthakrishnan AN, Mcginley EL, et al. Deep vein thrombosis and pulmonary embolism in hospitalized patients with cirrhosis: a nationwide analysis. Digest Dis Sci. 2011;56:2152–9.
Kamran BL, Katayon H, Dorna M, et al. Risk factors for portal vein thrombosis in patients with cirrhosis awaiting liver transplantation in Shiraz, Iran. Hepat Mon. 2015;15:e26407.
Jacobs BS, Levine SR. Antiphospholipid antibody syndrome. Curr Treat Options Neurol. 2012;2:449–57.
Soule H R, Brunck T K. Blood coagulation protein antagonists and uses therefor: EP, US 6221659 B1[P]. 2001.
Weingarten MA, Sande AA. Acute liver failure in dogs and cats. J Vet Emerg Crit Care. 2015;25:455–73.
Asakura H. Classifying types of disseminated intravascular coagulation: clinical and animal models. J Intensive Care. 2014;2:1–7.
Seth D, Haber PS, Syn WK, et al. Pathogenesis of alcohol-induced liver disease: classical concepts and recent advances. J Gastroenterol Hepatol. 2011;26:1089–105.
Collen D. Thrombin-antithrombin III and plasmin-antiplasmin complexes as indicators of in vivo activation of the coagulation and/or fibrinolytic systems. Pier Working Paper Archive. 2006;32:398–402.
Giannoni P, Pietra G, Travaini G, et al. Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages. Haematologica. 2014;99:1078–87.
Pluta A, Gutkowski K, Hartleb M. Coagulopathy in liver diseases. Adv Med Sci. 2010;55:16–21.
Jablonka W, Kotsyfakis M, Mizurini DM, et al. Identification and mechanistic analysis of a novel tick-derived inhibitor of thrombin. PLoS One. 2014;10:e0133991.
Gajos G, Zalewski J, Undas A. Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in diabetics with high cardiovascular risk. J Am Coll Cardiol. 2015;65:476–80.
Weijers EM, Wijhe MHV, Joosten L, et al. Molecular weight fibrinogen variants alter gene expression and functional characteristics of human endothelial cells. J Thromb Haemost. 2010;8:2800–9.
Chen CS, Cumbler EU, Triebling AT. Coagulopathy due to celiac disease presenting as intramuscular hemorrhage. J Gen Intern Med. 2007;22:1608–12.
Birchall J, Doree C, Gill R, et al. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev. 2011;20:93–103.
Wang L, Bastarache JA, Ware LB. The coagulation cascade in sepsis. Curr Pharm Des. 2008;14:1860–9.
Abdel-Razik A, Mousa N, Elhelaly R, et al. De-novo portal vein thrombosis in liver cirrhosis: risk factors and correlation with the model for end-stage liver disease scoring system. Eur J Gastroenterol Hepatol. 2015;27:585–92.
Baumann Kreuziger LM, Datta YH, Johnson AD, et al. Monitoring anticoagulation in patients with an unreliable PT/INR: factor II versus chromogenic factor X testing. Am J Hematol. 2014;87
Tripodi A, Chantarangkul V, Primignani M, et al. The international normalized ratio calibrated for cirrhosis (INR liver) normalizes prothrombin time results for model for end-stage liver disease calculation †. Hepatology. 2007;46(2):520–7.
Shiozawa Y, Fujita H, Fujimura J, et al. A fetal case of transient abnormal myelopoiesis with severe liver failure in Down syndrome: prognostic value of serum markers. Pediatr Hematol Oncol. 2004;21:273–8.
Liu XY, Hu JH, Wang HF. Analysis of prognostic factors for patients with acute-on-chronic liver failure. Chin J Hepatol. 2009;17:607–10.
Lippi G, Favaloro EJ. Activated partial thromboplastin time: new tricks for an old dogma. Semin Thromb Hemost. 2008;34:604–11.
Wu SJ, Yan HD, Zheng ZX, et al. Establishment and validation of ALPH-Q score to predict mortality risk in patients with acute-on-chronic hepatitis B liver failure: a prospective cohort study. Medicine. 2015;94:e403.
Tobias JD, Berkenbosch JW. Synthetic factor VIIa concentrate to treat coagulopathy and gastrointestinal bleeding in an infant with end-stage liver disease. Clin Pediatr. 2002;41:613–6.
Chen J, Duan ZP, Bai L, et al. Changing characteristic of blood coagulation factors and their correlation with blood coagulation status in different hepatic diseases. Chin J Hepatol. 2012;20:206–10.
Berkessy S. The plasma-protamine-paracoagulation-(3-P-) test. Zeitschrift Für Die Gesamte Innere Medizin Und Ihre Grenzgebiete. 1974;29:491–3.
Timan IS, Aulia D, Enny. The use of ethanol gelation test to screen the activation of coagulation and disseminated intravascular coagulation. J Lab Med Qual Assur, 2003, 25:231–235.
Venkata NRE, Divakar G. An overview on microbial fibrinolytic proteases. Int J Pharm Sci Res. 2014;5:643–56.
Nair GB, Lajin M, Muslimani A. A cirrhotic patient with spontaneous intramuscular hematoma due to primary hyperfibrinolysis. Clin Adv Hematol Oncol. 2011;9:249–52.
Sartori MT, Spiezia L, Cesaro S, et al. Role of fibrinolytic and clotting parameters in the diagnosis of liver veno-occlusive disease after hematopoietic stem cell transplantation in a pediatric population. Thromb Haemost. 2005;93:682–9.
Koyama K, Madoiwa S, Nunomiya S, et al. Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study. Crit Care. 2014;18:1–11.
Seto WK, Lai CL, Yuen MF. Acute-on-chronic liver failure in chronic hepatitis B. J Gastroenterol Hepatol. 2012;27:662–9.
Zanetto A, Senzolo M, Ferrarese A, et al. Assessment of bleeding risk in patients with cirrhosis. Curr Hepatol Rep. 2015;14:9–18.
Bailey MA, Griffin KJ, Sohrabi S, et al. Plasma thrombin-antithrombin complex, prothrombin fragments 1 and 2, and D-dimer levels are elevated after endovascular but not open repair of infrarenal abdominal aortic aneurysm. J Vasc Surg. 2013;57:1512–8.
Lisman T, Bakhtiari K, Adelmeijer J, et al. Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure. J Thromb Haemost. 2012;10:1312–9.
Aso Y, Matsumoto S, Fujiwara Y, et al. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1. Metabolism. 2002;51:471–6.
Levi M, De JE, Meijers J. The diagnosis of disseminated intravascular coagulation. Blood Rev. 2003;16:217–23.
Kawasugi K, Wada H, Hatada T, et al. Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases. Thromb Res. 2011;128:186–90.
Tang XH, Qiang LI, Lin WH, et al. Establishment and evaluation of a modified plasma protamine paracoagulation test. J Southern Med Univ. 2011;31:1626–8.
Olson JD. D-dimer: an overview of hemostasis and fibrinolysis, assays, and clinical applications. Adv Clin Chem. 2015;69:1–46.
Lippi G, Favaloro EJ, Cervellin G. Massive posttraumatic bleeding: epidemiology, causes, clinical features, and therapeutic management. Semin Thromb Hemost. 2013;39:83–93.
Bhalla A, Suri V, Singh V. Malarial hepatopathy. J Postgrad Med. 2006;52:315–20.
Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. J Intensive Care. 2014;2:15.
Heuft MM, Houba SM, Ge VDB, et al. Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection. AIDS. 2014;28:999–1005.
Kozeklangenecker SA. Fluids and coagulation. Curr Opin Crit Care. 2015;21:517–24.
Bhatia V, Lodha R. Upper gastrointestinal bleeding. Indian J Pediatr. 2011;78:227–33.
Seo YS, Kim YH, Ahn SH, et al. Clinical features and treatment outcomes of upper gastrointestinal bleeding in patients with cirrhosis. J Korean Med Sci. 2008;23:635–43.
Franchis RD. Somatostatin, somatostatin analogues and other vasoactive drugs in the treatment of bleeding oesophageal varices. Dig Liver Dis. 2004;36(Suppl 1):S93–S100.
Barkun AN, Sarvee M, Myriam M. Topical hemostatic agents: a systematic review with particular emphasis on endoscopic application in GI bleeding. Gastrointest Endosc. 2013;77:692–700.
Olsen KM. Use of acid-suppression therapy for treatment of non-variceal upper gastrointestinal bleeding. Am J Health Syst Pharm. 2005;62:18–23.
Bosch J, Abraldes JG, Berzigotti A, et al. Portal hypertension and gastrointestinal bleeding. Semin Liver Dis. 2008;28:3–25.
Tan XP. Observed the effect of Improved three-balloon catheter tube method in cirrhotic patients with gastrointestinal bleeding. Today Nurse. 2014;
Barkun A, Sabbah S, Enns R, et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol. 2004;99:1238–46.
Jovanovic I, Vormbrock K, Wilcox CM, et al. Therapeutic and interventional endoscopy for gastrointestinal bleeding. Eur J Trauma Emerg Surg. 2011;37:339–51.
Dempfle CE, Borggrefe M. Disseminated intravascular coagulation. Intensivmedizin Und Notfallmedizin. 2006;43:103–10.
Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31–41.
Yamanouchi M, Ubara Y, Mise K, et al. Hemodialysis without Anticoagulation for a Patient with Chronic Disseminated Intravascular Coagulation. Case Rep Nephrol Urol. 2014;4:25–30.
Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jimenez W, Arroyo V, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology. 2005;41:1282–9.
Ginės P, Guevara M, Arroyo V, et al. Hepatorenal syndrome. Lancet. 2003;362:1819–27.
O’Grady JG. Clinical disorders of renal function in acute liver failure. In: Gines P, Arroyo V, Rodes J, Schrier RW, editors. Ascites and renal dysfunction in liver disease. 2nd ed. Oxford: Blackwell Publishing; 2005. p. 383–93.
Flint A. Clinical report on hydroperitoneum based on analysis of 46 cases. Am J MedSci. 1963;45:306e39.
Bartoli E, Chiandussi L, editors. Hepato-Renal Syndrome. Padua: Piccin Medical Books; 1979.
Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Int Ascites Club Hepatol. 1996;23:164e76.
Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56:1310–8.
Wong F, Nadim MK, Kellum JA, Salerno F, Bellomo R, Gerbes A, Angeli P, et al. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut. 2011;60:702–9.
Davis CL, Feng S, Sung R, Wong F, Goodrich NP, Melton LB, Reddy KR, et al. Simultaneous liver-kidney transplantation: evaluation to decision making. Am J Transplant. 2007;7:1702–9.
Laleman W. Role of vasoactive substances and cellular effectors in the pathophysiology of cirrhotic portal hypertension: the past, the present and the future--Georges Brohe’e Lecture. Acta Gastroenterol Belg. 2009;72:9e16.
Colle I, Geerts AM, Van Steenkiste C, et al. Hemodynamic changes in splanchnic blood vessels in portal hypertension. Anat Rec (Hoboken). 2008;291:699e713.
Rodrìguez-Vilarrupla A, Fernàndez M, Bosch J, et al. Current concepts on the pathophysiology of portal hypertension. Ann Hepatol. 2007;6:28e36.
Blendis L, Wong F. The hyperdynamic circulation in cirrhosis: an overview. Pharmacol Ther. 2001;89:221e31.
Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004;40:55e64.
Wong F, Sniderman K, Liu P, et al. The effects of transjugular intrahepatic portosystemic shunt on systemic and renal hemodynamics and sodium homeostasis in cirrhotic patients with refractory ascites. Ann Intern Med. 1995;122:816e22.
Arroyo V, Terra C, Gines P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol. 2007;46:935e46.
Bernadich C, Bandi JC, Piera C, et al. Circulatory effects of graded diversion of portal blood flow to the systemic circulation in rats: role of nitric oxide. Hepatology. 1997;26:262e7.
Bosch J, Pizcueta MP, Fernandez M, et al. Hepatic, splanchnic and systemic haemodynamic abnormalities in portal hypertension. Baillieres Clin Gastroenterol. 1992;6:425e36.
Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology. 2008;48:2064–77.
Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8:1151–7.
Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006;43:S121–31.
Ginès A, Escorsell A, Ginès P, et al. Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105:229–36.
Lata J. Hepatorenal syndrome. World J Gastroenterol. 2012;18:4978–84.
Salerno F, Cazzaniga M, Merli M, Spinzi G, Saibeni S, Salmi A, Fagiuoli S, et al. Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice. J Hepatol. 2011;55:1241–8.
Zakim B, et al. Hepatology [M]. 6th ed: Elsevier Medicine; 2011.
Seu P, Wilkinson AH, Shaked A, et al. The hepatorenal syndrome in liver transplant recipients. Ann Surg. 1991;57:806–9.
Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134:1360–8.
Martin-Llahi M, Pepin MN, Guevara M, Diaz F, Torre A, Monescillo A, Soriano G, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008;134:1352–9.
Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 2002;122:923–30.
Solanki P, Chawla A, Garg R, et al. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol. 2003;18:152–6.
Lavayssiere L, Kallab S, Cardeau-Desangles I, et al. Impact of molecular adsorbent recirculating system on renal recovery in type-1 hepatorenal syndrome patients with chronic liver failure. J Gastroenterol Hepatol. 2013;28:1019–24.
Wong F, Raina N, Richardson R. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis and ascites who have failed vasoconstrictor treatment. Gut. 2010;59:381–6.
Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled clinical trial. Liver Transpl. 2000;6:277–86.
Heemann U, Treichel U, Loock J, et al. A dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology. 2002;36:949–58.
Ochs A, Rössle M, Haag K, Hauenstein KH, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med. 1995;332:1192–7.
Somberg KA, Lake JR, Tomlanovich SJ, et al. Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function. Hepatology. 1995;21:709–16.
Ginès P, Uriz J, Calahorra B, Garcia-Tsao G, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology. 2002;123:1839–47.
Michl P, Gulberg V, Bilzer M, Waggershauser T, Reiser M, Gerbes AL. Transjugular intrahepatic portosystemic shunt for cirrhosis and ascites: effects in patients with organic or functional renal failure. Scand J Gastroenterol. 2000;35:654–8.
Marcela K. Hepatorenal syndrome. World J Gastroenterol. 2012;18(36):4978–84.
Fasolato S, Angeli P, Dallagnese L, et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology. 2007;45:223–9.
Thabut D, Massard J, Gangloff A, et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology. 2007;46:1872–82.
Dundar HZ, Yılmazlar T, et al. Management of hepatorenal syndrome. World J Nephrol. 2015 May 6;4(2):277–86.
Fernandez J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007;133:818–24.
Huang K, Hu JH, Wang HF, He WP, Chen J, Duan XZ, Zhang AM, Liu XY. Survival and prognostic factors in hepatitis B virus-related acute-on-chronic liver failure. World J Gastroenterol. 2011;17(29):3448–52.
Kaufman CE, Mckee PA. Essentials of pathophysiology. 1st ed. Beijing: Peaking Union Medical College Press; 2002. p. 547.
Jianzhi W, Huiming J. Textbook of pathophysiology. 1st ed. Beijing: People’s Medical Publishing House; 2007. p. 13.
Juha P Kokko. Disorder of fluid volume, electrolyte, and acid-base balance. J Claude Bennett, FredPlum. Cecil textbook of medicine. 20th ed. W.B.Saunders company, 1996, 525.
Henriksen JH, Bendtsen F, Møller S. Acid-base disturbance in patients with cirrhosis: relation to hemodynamic dysfunction. Eur J Gastroenterol Hepatol. 2015 Aug;27(8):920–7.
Benjaminov FS. The pathophysiology of ascites formation in cirrhosis of the liver. Harefuah. 2002 Aug;141(8):721–5.
Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, Thompson CJ. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013 Oct;126(10 Suppl 1):S1–42.
Cárdenas A, Solà E, Rodríguez E, Barreto R, Graupera I, Pavesi M, Saliba F, Welzel T, Martinez-Gonzalez J, Gustot T, Bernardi M, Arroyo V, Ginès P; CANONIC study investigators of the EASL-CLIF Consortium. Hyponatremia influences the outcome of patients with acute-on-chronic liver failure: an analysis of the CANONIC study. Crit Care. 2014, 18(6):700.
Diercks DB, Shumaik GM, Harrigan RA, Brady WJ, Chan TC. Electrocardiographic manifestations: electrolyte abnormalities. J Emerg Med. 2004;27(2):153–60.
Li XM, Li YX, Meng QH, Duan ZH, Hou W, Li J. Characteristics of acid-base balance in patients with chronic severe hepatitis: analysis of 126 cases. Zhonghua Yi Xue Za Zhi. 2006 Aug 15;86(30):2131–3(in Chinese).
Kaufman CE, Mckee PA. Essentials of pathophysiology. 1st ed. Beijing: Peaking Union Medical College Press; 2002. p. 569.
Abelow B. Understanding acid-base. 1st ed. Baltimore: Lippincott, Williams&Wilkins; 1998. p. 51.
Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, et al. Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35:716–21.
(2013) [Consensus on the diagnosis and treatment of hepatic encephalopathy]. Zhonghua Gan Zang Bing Za Zhi 21: 641–651.
Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, et al. Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther. 2011;33:739–47.
Lauridsen MM, Poulsen L, Rasmussen CK, Hogild M, Nielsen MK, et al. Effects of common chronic medical conditions on psychometric tests used to diagnose minimal hepatic encephalopathy. Metab Brain Dis. 2016;31:267–72.
Tripathi S, Tripathi YB. Hepatic encephalopathy: cause and possible management with botanicals. Recent Patents Inflamm Allergy Drug Discov. 2014;8:185–91.
Butterworth RF. Pathophysiology of brain dysfunction in hyperammonemic syndromes: The many faces of glutamine. Mol Genet Metab. 2014;113:113–7.
Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2010;7:515–25.
Ott P, Vilstrup H. Cerebral effects of ammonia in liver disease: current hypotheses. Metab Brain Dis. 2014;29:901–11.
Jones EA, Mullen KD. Theories of the pathogenesis of hepatic encephalopathy. Clin Liver Dis. 2012;16:7–26.
Gooday R, Hayes PC, Bzeizi K, O’Carroll RE. Benzodiazepine receptor antagonism improves reaction time in latent hepatic encephalopathy. Psychopharmacology. 1995;119:295–8.
Jones EA. Ammonia, the GABA neurotransmitter system, and hepatic encephalopathy. Metab Brain Dis. 2002;17:275–81.
Montana V, Verkhratsky A, Parpura V. Pathological role for exocytotic glutamate release from astrocytes in hepatic encephalopathy. Curr Neuropharmacol. 2014;12:324–33.
Ding S, Yang J, Liu L, Ye Y, Wang X, et al. Elevated dopamine induces minimal hepatic encephalopathy by activation of astrocytic NADPH oxidase and astrocytic protein tyrosine nitration. Int J Biochem Cell Biol. 2014;55:252–63.
Holecek M. Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy-therapeutic perspectives. Metab Brain Dis. 2014;29:9–17.
Kobtan AA, El-Kalla FS, Soliman HH, Zakaria SS, Goda MA. Higher Grades and Repeated Recurrence of Hepatic Encephalopathy May Be Related to High Serum Manganese Levels. Biol Trace Elem Res. 2016;169:153–8.
Holecek M. Ammonia and amino acid profiles in liver cirrhosis: effects of variables leading to hepatic encephalopathy. Nutrition. 2015;31:14–20.
Shawcross DL, Wright G, Olde Damink SW, Jalan R. Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis. 2007;22:125–38.
Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol. 2004;40:247–54.
Merola J, Chaudhary N, Qian M, Jow A, Barboza K, et al. Hyponatremia: a risk factor for early overt encephalopathy after transjugular intrahepatic portosystemic shunt creation. J Clin Med. 2014;3:359–72.
Gaduputi V, Chandrala C, Abbas N, Tariq H, Chilimuri S, et al. Prognostic significance of hypokalemia in hepatic encephalopathy. Hepato-Gastroenterology. 2014;61:1170–4.
Tsai CF, Chen MH, Wang YP, Chu CJ, Huang YH, et al. Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in population study. Gastroenterology. 2016;
Jepsen P, Christensen J, Weissenborn K, Watson H, Vilstrup H. Epilepsy as a risk factor for hepatic encephalopathy in patients with cirrhosis: a cohort study. BMC Gastroenterol. 2016;16:77.
Casadaban LC, Parvinian A, Minocha J, Lakhoo J, Grant CW, et al. Clearing the confusion over hepatic encephalopathy after tips creation: incidence, prognostic factors, and clinical outcomes. Dig Dis Sci. 2015;60:1059–66.
Wang JY, Zhang NP, Chi BR, Mi YQ, Meng LN, et al. Prevalence of minimal hepatic encephalopathy and quality of life evaluations in hospitalized cirrhotic patients in China. World J Gastroenterol. 2013;19:4984–91.
Borentain P, Soussan J, Resseguier N, Botta-Fridlund D, Dufour JC, et al. The presence of spontaneous portosystemic shunts increases the risk of complications after transjugular intrahepatic portosystemic shunt (TIPS) placement. Diagn Interv Imaging. 2016;97:643–50.
Nardelli S, Gioia S, Pasquale C, Pentassuglio I, Farcomeni A, et al. Cognitive impairment predicts the occurrence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Am J Gastroenterol. 2016;111:523–8.
Brenner M, Butz M, May ES, Kahlbrock N, Kircheis G, et al. Patients with manifest hepatic encephalopathy can reveal impaired thermal perception. Acta Neurol Scand. 2015;132:156–63.
Kircheis G, Fleig WE, Gortelmeyer R, Grafe S, Haussinger D. Assessment of low-grade hepatic encephalopathy: a critical analysis. J Hepatol. 2007;47:642–50.
Hassanein TI, Hilsabeck RC, Perry W. Introduction to the Hepatic Encephalopathy Scoring Algorithm (HESA). Dig Dis Sci. 2008;53:529–38.
Ong JP, Aggarwal A, Krieger D, Easley KA, Karafa MT, et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med. 2003;114:188–93.
Qureshi MO, Khokhar N, Shafqat F. Ammonia levels and the severity of hepatic encephalopathy. J Coll Physicians Surg Pak. 2014;24:160–3.
Haussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut. 2008;57:1156–65.
Dabos KJ, Parkinson JA, Sadler IH, Plevris JN, Hayes PC. (1)H nuclear magnetic resonance spectroscopy-based metabonomic study in patients with cirrhosis and hepatic encephalopathy. World J Hepatol. 2015;7:1701–7.
Amodio P, Campagna F, Olianas S, Iannizzi P, Mapelli D, et al. Detection of minimal hepatic encephalopathy: normalization and optimization of the Psychometric Hepatic Encephalopathy Score. A neuropsychological and quantified EEG study. J Hepatol. 2008;49:346–53.
Sharma P, Sharma BC, Puri V, Sarin SK. Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy. J Hepatol. 2007;47:67–73.
Romero-Gomez M, Cordoba J, Jover R, del Olmo JA, Ramirez M, et al. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology. 2007;45:879–85.
Olesen SS, Gram M, Jackson CD, Halliday E, Sandberg TH, et al. Electroencephalogram variability in patients with cirrhosis associates with the presence and severity of hepatic encephalopathy. J Hepatol. 2016;65:517–23.
Jackson CD, Gram M, Halliday E, Olesen SS, Sandberg TH, et al. New spectral thresholds improve the utility of the electroencephalogram for the diagnosis of hepatic encephalopathy. Clin Neurophysiol. 2016;127:2933–41.
Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. Hepatology. 2009;50:2014–21.
Maharshi S, Sharma BC, Sachdeva S, Srivastava S, Sharma P. Efficacy of nutritional therapy for patients with cirrhosis and minimal hepatic encephalopathy in a randomized trial. Clin Gastroenterol Hepatol. 2016;14:454–60.
Amodio P, Canesso F, Montagnese S. Dietary management of hepatic encephalopathy revisited. Curr Opin Clin Nutr Metab Care. 2014;17:448–52.
Sawhney R, Jalan R. Liver: the gut is a key target of therapy in hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2015;12:7–8.
Rahimi RS, Singal AG, Cuthbert JA, Rockey DC. Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern Med. 2014;174:1727–33.
Rahimi RS, Rockey DC. Novel ammonia-lowering agents for hepatic encephalopathy. Clin Liver Dis. 2015;19:539–49.
Rai R, Ahuja CK, Agrawal S, Kalra N, Duseja A, et al. Reversal of low-grade cerebral edema after lactulose/rifaximin therapy in patients with cirrhosis and minimal hepatic encephalopathy. Clin Transl Gastroenterol. 2015;6:e111.
Shavakhi A, Hashemi H, Tabesh E, Derakhshan Z, Farzamnia S, et al. Multistrain probiotic and lactulose in the treatment of minimal hepatic encephalopathy. J Res Med Sci. 2014;19:703–8.
Morgan MY, Hawley KE. Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial. Hepatology. 1987;7:1278–84.
Agrawal A, Sharma BC, Sharma P, Sarin SK. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol. 2012;107:1043–50.
Paik YH, Lee KS, Han KH, Song KH, Kim MH, et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J. 2005;46:399–407.
Bajaj JS, Barrett AC, Bortey E, Paterson C, Forbes WP. Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis. Aliment Pharmacol Ther. 2015;41:39–45.
Kimer N, Krag A, Moller S, Bendtsen F, Gluud LL. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther. 2014;40:123–32.
Mullen KD, Sanyal AJ, Bass NM, Poordad FF, Sheikh MY, et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol. 2014;e12392:1390–7.
Sidhu SS, Goyal O, Parker RA, Kishore H, Sood A. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy. Liver Int. 2016;36:378–85.
Lunia MK, Sharma BC, Sharma P, Sachdeva S, Srivastava S. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Clin Gastroenterol Hepatol. 2014;12:1003–1008.e1001.
Saab S, Suraweera D, Au J, Saab EG, Alper TS, et al. Probiotics are helpful in hepatic encephalopathy: a meta-analysis of randomized trials. Liver Int. 2016;36:986–93.
Sharma P, Sharma BC, Puri V, Sarin SK. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2008;20:506–11.
Dhiman RK, Rana B, Agrawal S, Garg A, Chopra M, et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology. 2014;147:1327–37.
Matoori S, Leroux JC. Recent advances in the treatment of hyperammonemia. Adv Drug Deliv Rev. 2015;90:55–68.
Diaz-Herrero MM, del Campo JA, Carbonero-Aguilar P, Vega-Perez JM, Iglesias-Guerra F, et al. THDP17 decreases ammonia production through glutaminase inhibition. A new drug for hepatic encephalopathy therapy. PLoS One. 2014;9:e109787.
Gluud LL, Vilstrup H, Morgan MY (2016) Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev: Cd003044.
Cauli O, Rodrigo R, Piedrafita B, Boix J, Felipo V. Inflammation and hepatic encephalopathy: ibuprofen restores learning ability in rats with portacaval shunts. Hepatology. 2007;46:514–9.
Poo JL, Gongora J, Sanchez-Avila F, Aguilar-Castillo S, Garcia-Ramos G, et al. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann Hepatol. 2006;5:281–8.
Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RS Jr, et al. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology. 2014;59:1073–83.
Mousa N, Abdel-Razik A, Zaher A, Hamed M, Shiha G, et al. The role of antioxidants and zinc in minimal hepatic encephalopathy: a randomized trial. Therap Adv Gastroenterol. 2016;9:684–91.
Abdelaziz RR, Elkashef WF, Said E. Tranilast reduces serum IL-6 and IL-13 and protects against thioacetamide-induced acute liver injury and hepatic encephalopathy. Environ Toxicol Pharmacol. 2015;40:259–67.
Blei AT. Is it worth removing albumin-bound substances in hepatic encephalopathy? Z Gastroenterol. 2001;39(Suppl 2):8.
Gluud LL, Dam G, Les I, Cordoba J, Marchesini G, et al. (2015) Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev: Cd001939.
Morgan MY, Blei A, Grungreiff K, Jalan R, Kircheis G, et al. The treatment of hepatic encephalopathy. Metab Brain Dis. 2007;22:389–405.
Ahboucha S, Butterworth RF. The neurosteroid system: implication in the pathophysiology of hepatic encephalopathy. Neurochem Int. 2008;52:575–87.
Torres-Vega MA, Vargas-Jeronimo RY, Montiel-Martinez AG, Munoz-Fuentes RM, Zamorano-Carrillo A, et al. Delivery of glutamine synthetase gene by baculovirus vectors: a proof of concept for the treatment of acute hyperammonemia. Gene Ther. 2015;22:58–64.
Bai M, He C, Yin Z, Niu J, Wang Z, et al. Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS. Aliment Pharmacol Ther. 2014;40:63–71.
Luo L, Fu S, Zhang Y, Wang J. Early diet intervention to reduce the incidence of hepatic encephalopathy in cirrhosis patients: post-Transjugular Intrahepatic Portosystemic Shunt (TIPS) findings. Asia Pac J Clin Nutr. 2016;25:497–503.
Lynn AM, Singh S, Congly SE, Khemani D, Johnson DH, et al. Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy. Liver Transpl. 2016;22:723–31.
Hung PC, Wang HS, Hsia SH, Wong AM. Plasmapheresis as adjuvant therapy in Stevens-Johnson syndrome and hepatic encephalopathy. Brain and Development. 2014;36:356–8.
Wong RJ, Gish RG, Ahmed A. Hepatic encephalopathy is associated with significantly increased mortality among patients awaiting liver transplantation. Liver Transpl. 2014;20:1454–61.
Atluri DK, Asgeri M, Mullen KD. Reversibility of hepatic encephalopathy after liver transplantation. Metab Brain Dis. 2010;25:111–3.
Fallon MB, Abrams GA. Pulmonary dysfunction in chronic liver disease. Hepatology. 2000;32(4 Pt 1):859–65.
Lange PA, Stoller JK. The hepatopulmonary syndrome. Ann Intern Med. 1995;122(7):521–9.
Ford RM, Sakaria SS, Subramanian RM. Critical care management of patients before liver transplantation. Transplant Rev (Orlando). 2010;24(4):190–206.
Fuhrmann V, Jager B, Zubkova A, Drolz A. Hypoxic hepatitis - epidemiology, pathophysiology and clinical management. Wien Klin Wochenschr. 2010;122(5–6):129–39.
Breuer O, Shteyer E, Wilschanski M, Perles Z, Cohen-Cymberknoh M, Kerem E, Shoseyov D. Hepatopulmonary Syndrome in Patients With Cystic Fibrosis and Liver Disease. Chest. 2016;149(2):e35–8.
Pouriki S, Alexopoulou A, Chrysochoou C, Raftopoulos L, Papatheodoridis G, Stefanadis C, Pectasides D. Left ventricle enlargement and increased systolic velocity in the mitral valve are indirect markers of the hepatopulmonary syndrome. Liver Int. 2011;31(9):1388–94.
Rodriguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome--a liver-induced lung vascular disorder. N Engl J Med. 2008;358(22):2378–87.
Zhang ZJ, Yang CQ. Progress in investigating the pathogenesis of hepatopulmonary syndrome. Hepatobiliary Pancreat Dis Int. 2010;9(4):355–60.
Schenk P, Schoniger-Hekele M, Fuhrmann V, Madl C, Silberhumer G, Muller C. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology. 2003;125(4):1042–52.
Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology. 2005;41(5):1122–9.
Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet. 2004;363(9419):1461–8.
Schenk P, Fuhrmann V, Madl C, Funk G, Lehr S, Kandel O, Muller C. Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut. 2002;51(6):853–9.
Krowka MJ, Fallon MB, Kawut SM, Fuhrmann V, Heimbach JK, Ramsay MA, Sitbon O, Sokol RJ. International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation. 2016;100(7):1440–52.
Krowka MJ. Hepatopulmonary syndrome: monitoring at your fingertip. Dig Dis Sci. 2011;56(6):1599–600.
Naeije R. Hepatopulmonary syndrome and portopulmonary hypertension. Swiss Med Wkly. 2003;133(11–12):163–9.
Goldberg DS, Fallon MB. The Art and Science of Diagnosing and Treating Lung and Heart Disease Secondary to Liver Disease. Clin Gastroenterol Hepatol. 2015;13(12):2118–27.
Cuadrado A, Diaz A, Iruzubieta P, Salcines JR, Crespo J. Hepatopulmonary syndromeGastroenterol Hepatol. 2015;38(6):398–408.
Mukaida N, Ishikawa Y, Ikeda N, Fujioka N, Watanabe S, Kuno K, Matsushima K. Novel insight into molecular mechanism of endotoxin shock: biochemical analysis of LPS receptor signaling in a cell-free system targeting NF-kappaB and regulation of cytokine production/action through beta2 integrin in vivo. J Leukoc Biol. 1996 Feb;59(2):145–51.
Raetz CR, Ulevitch RJ, Wright SD, Sibley CH, Ding A, Nathan CF. Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J. 1991;5:2652–60.
Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature. 2007 Oct 18;449(7164):819–26.
Raetz CRH. Biochemistry of endotoxins. Annu Annu Rev Biochem. 1990;59:129–70.
Giuliani A, Pirri G, Rinaldi AC. Antimicrobial peptides: the LPS connection. Methods Mol Biol. 2010;618:137–54.
Magalhães PO, Lopes AM, Mazzola PG, Rangel-Yagui C, Penna TC, Pessoa A Jr. Methods of endotoxin removal from biological preparations: a review. J Pharm Pharm Sci. 2007;10(3):388–404.
Eckburg PB, Bik EM, Bernstein CN. Diversity of the human intestinal microbial flora. Science. 2005;308:1635–8.
Cullen TW, Schofield WB, Barry NA, Putnam EE, Rundell EA, Trent MS, Degnan PH, Booth CJ, Yu H, Goodman AL. Gut microbiota. Antimicrobial peptide resistance mediates resilience of prominent gut commensals during inflammation. Science. 2015 Jan 9;347(6218):170–5.
Janelsins BM, Lu M, Datta SK. Altered inactivation of commensal LPS due to acyloxyacyl hydrolase deficiency in colonic dendritic cells impairs mucosal Th17 immunity. Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):373–378.
Landsberger M, Zhou J, Wilk S, Thaumüller C, Pavlovic D, Otto M, Whynot S, Hung O, Murphy MF, Cerny V, Felix SB, Lehmann C. Inhibition of lectin-like oxidized low-density lipoprotein receptor-1 reduces leukocyte adhesion within the intestinal microcirculation in experimental endotoxemia in rats. Crit Care. 2010;14(6):R223. doi: 10
Griffiths KL, Tan JK, O’Neill HC. Characterization of the effect of LPS on dendritic cell subset discrimination in spleen. J Cell Mol Med. 2014;18(9):1908–12.
Nguyen DN, Jiang P, Jacobsen S, Sangild PT, Bendixen E, Chatterton DE. Protective effects of transforming growth factor β2 in intestinal epithelial cells by regulation of proteins associated with stress and endotoxin responses. PLoS One. 2015;10(2):e0117608.
Thompson PA, Kitchens RL. Native high-density lipoprotein augments monocyte responses to lipopolysaccharide (LPS) by suppressing the inhibitory activity of LPS-binding protein. J Immunol. 2006;177(7):4880–7.
Strandberg KL, Richards SM, Tamayo R, Reeves LT, Gunn JS. An altered immune response, but not individual cationic antimicrobial peptides, is associated with the oral attenuation of Ara4N-deficient Salmonella enterica serovar Typhimurium in mice. PLoS One. 2012;7(11):e49588.
Mehrzad J, Dosogne H, De Spiegeleer B, Duchateau L, Burvenich C. Bovine blood neutrophil acyloxyacyl hydrolase (AOAH) activity during endotoxin and coliform mastitis. Vet Res. 2007;38(5):655–68.
Schmiel DH, Moran EE, Keiser PB, Brandt BL, Zollinger WD. Importance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against Neisseria meningitidis group B. Infect Immun. 2011 Oct;79(10):4146–56.
E Ravikumar V, Shivashangari KS, Devaki T Effect of Tridax procumbens on liver antioxidant defense system during lipopolysaccharide-induced hepatitis in D-galactosamine sensitised rats. Mol Cell Biochem 2005;269(1–2):131–136.
Zhou H, Liang H, Li ZF, Xiang H, Liu W, Li JG. Vagus nerve stimulation attenuates intestinal epithelial tight junctions disruption in endotoxemic mice through α7 nicotinic acetylcholine receptors. Shock. 2013;40(2):144–51.
Hayani KC, Guerrero ML, Ruiz-Palacios GM, Gomez HF, Cleary TG. Evidence for long-term memory of the mucosal immune system: milk secretory immunoglobulin A against Shigella lipopolysaccharides. J ClinMicrobiol. 1991 Nov;29(11):2599–603.
Wang JH, Bose S, Kim GC, Hong SU, Kim JH, Kim JE, Kim H. Flos Lonicera ameliorates obesity and associated endotoxemia in rats through modulation of gut permeability and intestinal microbiota. PLoS One. 2014;9(1):e86117.
Wang H, Xu DX, Lv JW, Ning H, Wei W. Melatonin attenuates lipopolysaccharide (LPS)-induced apoptotic liver damage in D-galactosamine-sensitized mice. Toxicology. 2007;237(1–3):49–57.
JeralaR. Structural biology of the LPS recognition. Int J Med Microbiol 2007;297(5):353–363.
Wen M, Ma X, Cheng H, Jiang W, Xu X, Zhang Y, Zhang Y, Guo Z, Yu Y, Xu H, Qian C, Cao X, An H. Stk38 protein kinase preferentially inhibits TLR9-activated inflammatory responses by promoting MEKK2 ubiquitination in macrophages. Nat Commun. 2015;6:7167.
McDonald B, Jenne CN, Zhuo L, Kimata K, Kubes P. Kupffer cells and activation of endothelial TLR4 coordinate neutrophil adhesion within liver sinusoids during endotoxemia. Am J Physiol Gastrointest Liver Physiol. 2013;305(11):G797–806.
Barquero-Calvo E, Mora-Cartín R, Arce-Gorvel V, de Diego JL, Chacón-Díaz C, Chaves-Olarte E, Guzmán-Verri C, Buret AG, Gorvel JP, Moreno E. Brucella abortus induces the premature death of human neutrophils through the action of its lipopolysaccharide. PLoS Pathog. 2015;11(5):e1004853.
Zullo JA, Nadel EP, Rabadi MM, Baskind MJ, Rajdev MA, Demaree CM, Vasko R, Chugh SS, Lamba R, Goligorsky MS, Ratliff BB. The secretome of hydrogel-coembedded endothelial progenitor cells and mesenchymal stem cells instructs macrophage polarization in endotoxemia. Stem Cells Transl Med 2015 May 6. pii: sctm.2014-0111.
Zhang Y, Lu Y, Ma L, Cao X, Xiao J, Chen J, Jiao S, Gao Y, Liu C, Duan Z, Li D, He Y, Wei B, Wang H. Activation of vascular endothelial growth factor receptor-3 in macrophages restrains TLR4-NF-κB signaling and protects against endotoxin shock. Immunity. 2014;40(4):501–14.
Kaukonen KM, Bailey M, Pilcher D, Cooper DJ, Bellomo R. Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med. 2015;372(17):1629–38.
La Mura V, Pasarín M, Rodriguez-Vilarrupla A, García-Pagán JC, Bosch J, Abraldes JG. Liver sinusoidal endothelial dysfunction after LPS administration: a role for inducible-nitric oxide synthase. J Hepatol. 2014;61(6):1321–7.
Feng A, Zhou G, Yuan X, Huang X, Zhang Z, Zhang T. Inhibitory effect of baicalin on iNOS and NO expression in intestinal mucosa of rats with acute endotoxemia. PLoS One. 2013;8(12):e80997.
Han DW. Intestinal endotoxemia as a pathogenetic mechanism in liver failure. World J Gastroenterol. 2002;8(6):961–5.
Lv X, Song JG, Li HH, Ao JP, Zhang P, Li YS, Song SL, Wang XR. Decreased hepatic peroxisome proliferator-activated receptor-γ contributes to increased sensitivity to endotoxin in obstructive jaundice. World J Gastroenterol. 2011;17(48):5267–73.
Armstrong MT, Rickles FR, Armstrong PB. Capture of lipopolysaccharide (endotoxin) by the blood clot: a comparative study. PLoS One. 2013;8(11):e80192.
Tarao K. So K, Moroi T, Ikeuchi T, Suyama T. Detection of endotoxin in plasma and ascitic fluid of patients with cirrhosis: its clinical significance. Gastroenterology. 1977;73(3):539–42.
Zijlstra JG, Tulleken JE, Ligtenberg JJ, de Boer P, van der Werf TS. p38-MAPK inhibition and endotoxin induced tubular dysfunction in men. J Endotoxin Res. 2004;10(6):402–5.
Chastre A, Bélanger M, Nguyen BN, Butterworth RF. Lipopolysaccharide precipitates hepatic encephalopathy and increases blood-brain barrier permeability in mice with acute liver failure. Liver Int. 2014 Mar;34(3):353–61.
Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, BobbioPallavicini FM, Rottoli F, Giunta F, Ronco C. Early use of polymyxin B hemoperfusion in abdominal septic shock: The EUPHAS randomized controlled trial. JAMA. 2009;301:2445–52.
Yoshino N, Endo M, Kanno H, et al. Polymyxins as novel and safe mucosal adjuvants to induce humoral immune responses in mice. PLoS One. 2013;8(4):e61643.
Verhoef J, Visser MR. Neutrophil phagocytosis and killing: normal function and microbial evasion. The neutrophil; 1993. p. 109–37.
Baumberger C, Ulevitch RJ, Dayer JM. Modulation of endotoxic activity of lipopolysaccharide by high-density lipoprotein. Pathobiology. 1991;59:378–83.
Wittebole X, Castanares-Zapatero D, Laterre PF. Toll-like receptor 4 modulation as a strategy to treat sepsis. Mediat Inflamm. 2010;2010:568396.
Zanoni I, Ostuni R, Marek LR, et al. CD14 controls the LPS-induced endocytosis of Toll-like receptor 4. Cell. 2011;147(4):868–80.
Michlewska S, Dransfield I, Megson IL, et al. Macrophage phagocytosis of apoptotic neutrophils is critically regulated by the opposing actions of pro-inflammatory and anti-inflammatory agents: key role for TNF-α. FASEB J. 2009;23(3):844–54.
Baue AE. MOF, MODS, and SIRS: what is in a name or an acronym? Shock. 2006;26(5):438–49.
Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest J. 1992;101(6):1481–3.
Hunter JD, Doddi M. Sepsis and the heart. Br J Anaesth. 2010;104(1):3–11.
Brigham KL, Meyrick B. Endotoxin and lung injury. Am Rev Respir Dis. 1986;133(5):913–27.
Nolan JP. The role of intestinal endotoxin in liver injury: a long and evolving history. Hepatology. 2010;52(5):1829–35.
Wan L, Bagshaw SM, Langenberg C, Saotome T, May C, Bellomo R. Pathophysiology of septic acute kidney injury: What do we really know? Crit Care Med. 2008;36:S198–203.
Semeraro N, Ammollo CT, Semeraro F, et al. Sepsis, thrombosis and organ dysfunction. Thromb Res. 2012;129(3):290–5.
Yang R, Miki K, Oksala N, et al. Bile high-mobility group box 1 contributes to gut barrier dysfunction in experimental endotoxemia. Am J Phys Regul Integr Comp Phys. 2009;297(2):R362–9.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature B.V. and Huazhong University of Science and Technology Press
About this chapter
Cite this chapter
Song, JX. et al. (2019). Main Complications of AECHB and Severe Hepatitis B (Liver Failure). In: Ning, Q. (eds) Acute Exacerbation of Chronic Hepatitis B. Springer, Dordrecht. https://doi.org/10.1007/978-94-024-1603-9_2
Download citation
DOI: https://doi.org/10.1007/978-94-024-1603-9_2
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-024-1601-5
Online ISBN: 978-94-024-1603-9
eBook Packages: MedicineMedicine (R0)